HOUSTON--(BUSINESS WIRE)--Dr. James H. Kelly, Chief Executive Officer of Stem Cell Innovations, Inc. (OTCBB:SCLL), presented data yesterday at the Cold Spring Harbor Laboratory Germ Cell meeting describing further characterization of PluriCells™, the Company’s pluripotent human stem cell lines. Because these cells are derived from fetal tissue, not early embryos, they are eligible for use in laboratories funded by the National Institutes of Health.
